Oncology and Hematology

Episodes 49-64 of 392

HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
CME/CE
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
- Fernando López-Ríos, MD, PhD
- Christian Rolfo, MD, PhD
- Charlie Gourley, MD, PhD
Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
Project Oncology®
Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
Targeting CD123 in AML: The Latest Therapeutic Advancements
Targeting CD123 in AML: The Latest Therapeutic Advancements
Project Oncology®
Targeting CD123 in AML: The Latest Therapeutic Advancements
- Jennifer Caudle, DO
- Naval Daver, MD
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
Global Oncology Academy
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
- Mohit Khera, M.D., M.B.A., M.P.H.
Reevaluating Testosterone: A Paradigm Shift in Prostate Cancer Treatment
Reevaluating Testosterone: A Paradigm Shift in Prostate Cancer Treatment
Global Oncology Academy
Reevaluating Testosterone: A Paradigm Shift in Prostate Cancer Treatment
- Mohit Khera, M.D., M.B.A., M.P.H.
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Clinician's Roundtable
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
Global Oncology Academy
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
- Joseph Unger, PhD, MS
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
Global Oncology Academy
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
- William Aronson, MD
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Project Oncology®
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Hadfield, MD
From Diagnosis to Treatment: Challenges in Glioblastoma Care
From Diagnosis to Treatment: Challenges in Glioblastoma Care
NeuroFrontiers
From Diagnosis to Treatment: Challenges in Glioblastoma Care
- Lauren Schaff, MD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Etranacogene Dezaparvovec for Hemophilia B: Efficacy and Safety Four Years Post-Infusion
Etranacogene Dezaparvovec for Hemophilia B: Efficacy and Safety Four Years Post-Infusion
Clinician's Roundtable
Etranacogene Dezaparvovec for Hemophilia B: Efficacy and Safety Four Years Post-Infusion
- Brian P. McDonough, MD, FAAFP
- Guy Young, MD
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
CME/CE
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
0.50 credits
- Elizabeth R. Plimack, MD, MS, FASCO
- Shilpa Gupta, MD
0.50 credits